Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT.
about
The role of aflibercept in the management of diabetic macular edemaEFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Aflibercept: A Review of Its Use in Diabetic Macular Oedema.The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.Drug delivery techniques for treating age-related macular degeneration.Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.Aflibercept for the treatment of diabetic macular edema.Management of macular edema secondary to branch retinal vein occlusion in an eye with prior vitrectomy and lensectomyPharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.Subconjunctival bleb that forms at the injection site after intravitreal injection is drug, not vitreous.Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study.The efficacy and safety of aflibercept and conbercept in diabetic macular edema
P2860
Q26798348-E5961648-B2A1-45A8-BAA8-D16905995336Q30490563-CEE050C8-2C7E-435C-A15C-6192013FCF30Q34216877-FBCCF693-F671-4166-B57C-A7E0E0F5F476Q34624487-14A163E1-BA10-415D-999B-E9F71A0916E7Q35657595-437DAE4A-B566-43A7-A8F0-9C8F2B5CF176Q35998229-0832F005-F8AB-445A-8179-F54299DB5567Q36013973-D51F6562-4726-4DAA-A598-DD3D3E4E71CEQ36331045-4AFC4CA9-491E-4968-BE62-BFE6C892D7B3Q36752250-DAC0E28A-99D5-4B87-9B48-08C6F4F4597BQ38161953-74EC4D42-012F-45D8-860D-8A59589B39EDQ38168825-753EA359-EDAF-430A-9C54-5A3540E46D1FQ38205131-C61EB809-0657-404A-BF4C-06C3A36F9EA2Q38747162-910FFBF3-040A-4132-ABFB-34FB81F762B1Q42116625-B7722885-1B2A-4735-BE11-7301DC277177Q47405816-E4DE94D6-97C3-48C4-BA1D-D2CEBBD1D4B8Q51471678-E2DF9094-B055-4E13-A6B9-F00CB0407733Q54456225-A89B9331-7F90-4F17-AB37-459E52169B19Q55073223-DF211739-1395-4738-BF19-CFB815FFD133Q58562047-DB9A2518-B0D8-4DBB-BF76-C23E547A0026
P2860
Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@en
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@nl
type
label
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@en
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@nl
prefLabel
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@en
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetic properties of ...... n a rabbit model using PET/CT.
@en
P2093
Frank J Epitropoulos
John B Christoforidis
Krishan Kumar
Michael V Knopp
Michelle M Williams
Shankaran Kothandaraman
P2860
P304
P356
10.3109/02713683.2012.727521
P577
2012-09-19T00:00:00Z